Erasca

ERAS

Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

How is Erasca (ERAS) performing?

Erasca (ERAS) is up 0.0% today, trading at $14.23 with a daily range of $14.05 to $15.23. Over the past year, Erasca hit a 52-week high of $15.23 and a low of $14.05, and is up 0.0% year-to-date.

What is the market cap of Erasca (ERAS)?

Erasca (ERAS) has a market cap of -. To see how ERAS compares to other stocks, check out CoinGecko's list of stocks ranked by market cap.

Who are the different issuers of tokenized Erasca (ERAS)?

Ondo Finance is the only issuer of tokenized Erasca on CoinGecko. Their token, ERASON, has a market cap of -.

Where can I buy tokenized Erasca (ERAS)?

Tokenized Erasca (ERAS) is currently not available to trade on any exchanges listed on CoinGecko. Check back later — information will be updated when trading activity resumes.